» Articles » PMID: 25883554

Inflammation in Parkinson's Disease: Role of Glucocorticoids

Overview
Journal Front Neuroanat
Date 2015 Apr 18
PMID 25883554
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic inflammation is a major characteristic feature of Parkinson's disease (PD). Studies in PD patients show evidence of augmented levels of potent pro-inflammatory molecules e.g., TNF-α, iNOS, IL-1β whereas in experimental Parkinsonism it has been consistently demonstrated that dopaminergic neurons are particularly vulnerable to activated glia releasing these toxic factors. Recent genetic studies point to the role of immune system in the etiology of PD, thus in combination with environmental factors, both peripheral and CNS-mediated immune responses could play important roles in onset and progression of PD. Whereas microglia, astrocytes and infiltrating T cells are known to mediate chronic inflammation, the roles of other immune-competent cells are less well understood. Inflammation is a tightly controlled process. One major effector system of regulation is HPA axis. Glucocorticoids (GCs) released from adrenal glands upon stimulation of HPA axis, in response to either cell injury or presence of pathogen, activate their receptor, GR. GR regulates inflammation both through direct transcriptional action on target genes and by indirectly inhibiting transcriptional activities of transcriptional factors such as NF-κB, AP-1 or interferon regulatory factors. In PD patients, the HPA axis is unbalanced and the cortisol levels are significantly increased, implying a deregulation of GR function in immune cells. In experimental Parkinsonism, the activation of microglial GR has a crucial effect in diminishing microglial cell activation and reducing dopaminergic degeneration. Moreover, GCs are also known to regulate human brain vasculature as well as blood brain barrier (BBB) permeability, any dysfunction in their actions may influence infiltration of cytotoxic molecules resulting in increased vulnerability of dopamine neurons in PD. Overall, deregulation of glucocorticoid receptor actions is likely important in dopamine neuron degeneration through establishment of chronic inflammation.

Citing Articles

Longitudinal multi-omics in alpha-synuclein Drosophila model discriminates disease- from age-associated pathologies in Parkinson's disease.

Moore J, Wu T, Dhindsa J, El Fadel O, Le A, Perez A NPJ Parkinsons Dis. 2025; 11(1):46.

PMID: 40069190 PMC: 11897226. DOI: 10.1038/s41531-025-00899-z.


Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances.

Jiang Q, Liu J, Huang S, Wang X, Chen X, Liu G Signal Transduct Target Ther. 2025; 10(1):76.

PMID: 40059211 PMC: 11891338. DOI: 10.1038/s41392-025-02145-7.


CBD's potential impact on Parkinson's disease: An updated overview.

Hafida E, Rachid S, Halima G, Najib K Open Med (Wars). 2024; 19(1):20241075.

PMID: 39479465 PMC: 11524397. DOI: 10.1515/med-2024-1075.


Diffusion tensor metrics, motor and non-motor symptoms in de novo Parkinson's disease.

Soares N, da Silva P, Pereira G, Leoni R, Mello Rieder C, Alva T Neuroradiology. 2024; 66(11):1955-1966.

PMID: 39190159 DOI: 10.1007/s00234-024-03452-6.


FoxO1 Alleviates the Mitochondrial ROS Levels Induced by α-Synuclein Preformed Fibrils in BV-2 Microglial Cells.

Na J, Ryu H, Park H, Park H, Lee E, Nam Y Inflammation. 2024; .

PMID: 39145787 DOI: 10.1007/s10753-024-02119-x.


References
1.
Rosenfeld M, Glass C . Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem. 2001; 276(40):36865-8. DOI: 10.1074/jbc.R100041200. View

2.
Kurkowska-Jastrzebska I, Litwin T, Joniec I, Ciesielska A, Przybylkowski A, Czlonkowski A . Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int Immunopharmacol. 2004; 4(10-11):1307-18. DOI: 10.1016/j.intimp.2004.05.006. View

3.
Huang C, Lui C, Chang W, Lu C, Wang Y, Chang C . Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer's disease. J Clin Neurosci. 2009; 16(10):1283-6. DOI: 10.1016/j.jocn.2008.12.026. View

4.
Maetzler W, Apel A, Langkamp M, Deuschle C, Dilger S, Stirnkorb J . Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. PLoS One. 2014; 9(2):e88604. PMC: 3931625. DOI: 10.1371/journal.pone.0088604. View

5.
Ros-Bernal F, Hunot S, Herrero M, Parnadeau S, Corvol J, Lu L . Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A. 2011; 108(16):6632-7. PMC: 3080980. DOI: 10.1073/pnas.1017820108. View